Trial intelligence / Profile preview

Reduced-dose azacitidine + venetoclax vs azacitidine for maintenance in intermediate–adverse risk AML (MRD-negative CR1)

ChiCTR2500114525Phase 2Not yet recruiting

Sponsor

First Affiliated Hospital of Soochow University

Start

Dec 2025

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules

Countries

1